Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA (ENXTPA:OSE) on April 26, 2021. Pursuant to the transaction, OSE Immunotherapeutics will receive up to 315 million in potential milestones from Veloxis, including a 7 million upfront payment.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
6.42 EUR | +1.42% | +13.83% | +50.00% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.00% | 147M | |
+20.95% | 46.81B | |
-0.83% | 41.37B | |
+47.19% | 41.29B | |
-6.20% | 28.87B | |
+10.75% | 26.06B | |
-20.69% | 19.13B | |
+31.14% | 12.39B | |
+0.19% | 12.08B | |
-0.45% | 11.96B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.